Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Trial Profile

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Selonsertib (Primary) ; Prednisolone
  • Indications Alcoholic hepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Apr 2018 to 13 Sep 2018.
    • 13 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 13 Sep 2018.
    • 13 Sep 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top